Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific AntibodiesPRNewsWire • 01/19/21
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical TrialGlobeNewsWire • 01/12/21
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers SymposiumGlobeNewsWire • 01/11/21
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion CancersGlobeNewsWire • 01/07/21
Merus and Sema4 Enter Into an Agreement to Support Merus' Phase 1/2 Clinical Trial of ZenocutuzumabGlobeNewsWire • 12/17/20
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of CancerGlobeNewsWire • 11/09/20
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion TumorsGlobeNewsWire • 10/12/20
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic CancerGlobeNewsWire • 07/27/20
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer PatientsGlobeNewsWire • 07/13/20
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program UpdatesGlobeNewsWire • 05/14/20
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene FusionsGlobeNewsWire • 10/27/19
Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/25/19
Merus Announces Financial Results for the Second Quarter 2019 and Provides Business UpdateGlobeNewsWire • 08/19/19